A 24-month, Single Center, Pilot, Open Label, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Calcineurin-inhibitor Elimination or Reduction With Randomization at 3 Months to Everolimus/Myfortic Versus Reduced Dose Tacrolimus/Everolimus in Adult Renal Transplant Recipients Following Campath Induction and Steroid Avoidance.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Everolimus (Primary) ; Mycophenolate sodium; Tacrolimus
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 25 Feb 2021 Biomarkers information updated
- 11 Sep 2013 New trial record